Skip Navigation

European Heart Journal 1992 13(8):1129-1134;
Copyright © 1992 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by TZIVONI, D.
Right arrow Articles by STERN, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by TZIVONI, D.
Right arrow Articles by STERN, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1992 The European Society of Cardiology

Effect of benazepril on myocardial ischaemia in patients with chronic stable angina pectoris

D. TZIVONI*, S. GOTTLIEB, N. S. KHURMI, A. MEDINA, A. GAVISH and S. STERN

The Heiden Department of Cardiology, Bikur Cholim Hospital and the Hebrew University Hadassah Medical School Jerusalem, Israel

Received 3 June 1991; revised 16 October 1991; .

Shmuel Gottlieb, MD, The Heiden Department of Cardiology, Bikur Cholim Hospital, P.O.Box 492, Jerusalem 91002, Isreal

Abstract

The anti-ischaemic properties of benazepril, a non-sulfhydryl inhibitor of angiotensin-converting enzyme, were assessed in 20 patients with chronic stable angina pectoris, by repeated exercise tests and repeated 72-h ambulatory electrocardio-graphic monitoring. The study was a double-blind, placebo-controlled cross-over; 11 patients received benazepril 10 mg b.i.d. and nine received 20 mg b.i.d. All patients had a positive treadmill stress test and at least three ischaemic episodes during 24 h of ambulatory electrocardiographic monitoring.

Benazepril at a dose of 10 mg b.i.d. did not improve the exercise duration, the time taken to reach 1 mm ST depression. Similar findings were observed during treatment with 20 mg b.i.d. Benazepril at a dose of 10 mg b.i.d. was ineffective in improving ischaemic parameters during daily activities. However, among the nine patients who received 20 mg b.i.d. the number of ischaemic episodes was reduced from 142 to 103, and the total duration of ischaemia was reduced from 1099 to 531 min. The number of weekly anginal attacks was reduced from 58 to 33, and the weekly sublingual nitroglycerin tablets consumption was reduced from 31 to 14. When the two doses (10 mg and 20 mg) were combined (N = 20), the number of ischaemic episodes was reduced from 314 to 260 (P= 0.074), and the duration of ischaemia was reduced from 3453 to 2514 min (P = 0.072).

Key Words: Exercise testing • ambulatory ECG monitoring • ACE inhibitors • myocardial ischaemia • anti-ischaemic therapy


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Am Coll CardiolHome page
C. J. Pepine, J.-L. Rouleau, K. Annis, A. Ducharme, P. Ma, J. Lenis, R. Davies, U. Thadani, B. Chaitman, H. E. Haber, et al.
Effects of angiotensin-converting enzyme inhibition on transient ischemia: The quinapril anti-ischemia and symptoms of angina reduction (QUASAR) trial
J. Am. Coll. Cardiol., December 17, 2003; 42(12): 2049 - 2059.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
R. Willenheimer, E. Rydberg, L. Oberg, S. Juul-Moller, and L. Erhardt
ACE inhibition with ramipril improves left ventricular function at rest and post exercise in patients with stable ischaemic heart disease and preserved left ventricular systolic function
Eur. Heart J., November 2, 1999; 20(22): 1647 - 1656.
[Abstract] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.